These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 16990111

  • 1. Cladribine in hairy cell leukemia.
    Belani R, Saven A.
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
    [Abstract] [Full Text] [Related]

  • 2. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
    Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, Petrini M.
    Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063
    [Abstract] [Full Text] [Related]

  • 3. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
    Bengio R, Narbaitz M, Palacios F, Scolnik M, Sarmiento M.
    Medicina (B Aires); 2000 Dec; 60 Suppl 2():71-6. PubMed ID: 11188936
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
    Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P.
    Leukemia; 1994 Jul; 8(7):1153-6. PubMed ID: 7913513
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
    Zák P, Chrobák L, Dĕdic K, Podzimek K.
    Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
    [Abstract] [Full Text] [Related]

  • 9. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC.
    Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
    Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O'Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D.
    Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
    [Abstract] [Full Text] [Related]

  • 11. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
    Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D.
    Cancer; 2005 Dec 01; 104(11):2442-8. PubMed ID: 16245328
    [Abstract] [Full Text] [Related]

  • 12. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O, Tomová A, Kusenda J, Gyárfás J.
    Neoplasma; 2001 Dec 01; 48(5):350-7. PubMed ID: 11845978
    [Abstract] [Full Text] [Related]

  • 13. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W, Weltermann A, Chott A, Gisslinger H, Valent P, Jäger U, Geissler K, Lechner K.
    Wien Klin Wochenschr; 1999 Dec 23; 111(24):1027-30. PubMed ID: 10677889
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
    Tallman MS.
    Leuk Lymphoma; 2011 Jun 23; 52 Suppl 2():65-8. PubMed ID: 21463116
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
    Del Poeta G, Del Principe MI, Buccisano F, Maurillo L, Capelli G, Luciano F, Perrotti AP, Degan M, Venditti A, de Fabritiis P, Gattei V, Amadori S.
    Cancer; 2008 Jan 01; 112(1):119-28. PubMed ID: 17999417
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.